Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2001

View Archived Issues

Curis begins clinical evaluation of Vascugel in coronary artery disease

Atrix seeks FDA approval for one-month Leuprogel product

HspE7 granted orphan drug status from FDA for recurrent respiratory papillomatosis

Astra Zeneca seeks FDA approval for breast cancer treatment

Promising data reported from phase I trial of Esperion's ApoA-I Milano

Lumigan: a potent, long-acting and safe new IOP-lowering drug

Liposome-based formulation of mitoxantrone as a viable alternative to conventional drug

GPC Biotech reaches milestones in antimicrobial alliance with Byk Gulden

AACR news: novel fumagillin derivative CKD-732 as a component of combination chemotherapy

Shareholders overwhelmingly approve BioChem Pharma-Shire merger

Antiangiogenic therapies targeting both paracrine and autocrine VEGF signaling pathways

NeoTherapeutics begins phase II Parkinson's disease trial of Neotrofin

GlycoDesign expands GD-0039 clinical program

ImmunoGen and Raven to jointly develop novel antibody therapeutics for ovarian cancer

Research data on OSI-774 presented at AACR meeting

FDA grants priority review status for Entocort modified-release capsules

HGS initiates phase I trial of Albuferon as treatment for HCV

Autologous bone marrow cell implantation: a novel strategy for optimizing therapeutic angiogenesis

Raxofelast restores VEGF expression and stimulates healing, angiogenesis in diabetic mice

Design of new orally bioavailable factor Xa inhibitors reported at ACS

ACS news: A-292438 as a promising ETA-selective antagonist

DuPont R&D continues focus on potent, selective and orally active factor Xa inhibitors

Potent and selective 20-HETE synthase inhibitors under study at Taisho

New series of factor Xa inhibitors patented by Cor research group

Indole-based 5-HT2 receptor ligands described by Vernalis

Telik prepares novel glucose uptake promoters for use in type 2 diabetes

Angiogene claims compounds with the ability to damage newly formed vascular endothelium

Two new patents owned by Pharmacia cover CDK inhibitors

Nonpeptide inhibitors of VLA-4-mediated cell adhesion emerge from R&D at Biogen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...